🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

117+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 117 recruiting trials for “acute-myeloid-leukemia-with-t816p11p13-translocation

Phase 1RecruitingNCT06222580

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

👨‍⚕️ Uma M Borate, MD, MS, Ohio State University Comprehensive Cancer Center📍 3 sites📅 Started Feb 2024View details ↗
Phase 2RecruitingNCT05483010

Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)

👨‍⚕️ Amber Afzal, M.D., MSCI, Washington University School of Medicine📍 1 site📅 Started Feb 2024View details ↗
Phase 2RecruitingNCT06232655

Cladribine Venetoclax in Monocytic AML

👨‍⚕️ Christine McMahon, MD, University of Colorado, Denver📍 1 site📅 Started Feb 2024View details ↗
Phase 1RecruitingNCT06034470

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

👨‍⚕️ Jacob Appelbaum, MD, PhD, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Dec 2023View details ↗
Phase 1RecruitingNCT05947344

A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)

🏥 Zhejiang ACEA Pharmaceutical Co. Ltd.📍 1 site📅 Started Dec 2023View details ↗
RecruitingNCT06116318

A Study of c-Kit Mutation as MRD in Acute Myeloid Leukemia

🏥 Institute of Hematology & Blood Diseases Hospital, China📍 1 site📅 Started Nov 2023View details ↗
Phase 1RecruitingNCT05995041

Universal CAR-T Cells Targeting AML

🏥 Shenzhen Geno-Immune Medical Institute📍 1 site📅 Started Oct 2023View details ↗
NARecruitingNCT06066242

Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy

👨‍⚕️ Hui Wei, MD, Institute of Hematology & Blood Diseases Hospital, China📍 1 site📅 Started Oct 2023View details ↗
Phase 1RecruitingNCT06034275

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

👨‍⚕️ Vincerx Study Director, Vincerx Pharma, Inc.📍 5 sites📅 Started Sep 2023View details ↗
Enrolling by InvitationNCT05212103

PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9

👨‍⚕️ Anne Roivainen, Turku University Hospital, Turku PET Centre📍 1 site📅 Started Sep 2023View details ↗
Phase 1RecruitingNCT05735184

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

🏥 Kura Oncology, Inc.📍 44 sites📅 Started Jul 2023View details ↗
Phase 3RecruitingNCT05994690

CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients

👨‍⚕️ Gertjan Kaspers, Prof. Dr., Pediatric Oncologist📍 1 site📅 Started Jul 2023View details ↗
Phase 2RecruitingNCT05925504

The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes

🏥 Institute of Hematology & Blood Diseases Hospital, China📍 1 site📅 Started Jul 2023View details ↗
RecruitingNCT05902416

Clinical Registration Study of Haplo-HSCT for Elderly Patients With Acute Leukemia/ Myelodysplastic Syndrome

🏥 Peking University People's Hospital📍 1 site📅 Started Jun 2023View details ↗
RecruitingNCT05772559

Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction Studies

🏥 Assistance Publique - Hôpitaux de Paris📍 28 sites📅 Started May 2023View details ↗
Phase 1, PHASE2RecruitingNCT05732103

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

👨‍⚕️ Guillermo Garcia-Manero, MD, M.D. Anderson Cancer Center📍 7 sites📅 Started Apr 2023View details ↗
Phase 2RecruitingNCT05796570

A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies

👨‍⚕️ Franziska Wachter, MD, Dana-Farber Cancer Institute📍 2 sites📅 Started Apr 2023View details ↗
Phase 2RecruitingNCT05736965

A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia

🏥 Shanghai Tong Ren Hospital📍 19 sites📅 Started Feb 2023View details ↗
Phase 1RecruitingNCT05558124

CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML

👨‍⚕️ Onyee Chan, MD, Moffitt Cancer Center📍 1 site📅 Started Feb 2023View details ↗
Phase 3Enrolling by InvitationNCT05674539

Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome

👨‍⚕️ Linghui Xia, Professor, Department of Hematology, Wuhan Union Hospital, Tongji Medical college, Huazhong University of Science and Technology📍 1 site📅 Started Feb 2023View details ↗
← PreviousPage 4 of 6Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →